ERBB2 and breast carcinoma: Harvested DCs were then cocultured for a total of 5 h with HLA-A2+ T cells that comprised a measureable frequency of HER-2/neu specific T cells (derived from PBL of a breast cancer patient previously vaccinated with HER-2/neu369-377 [26]) or with MART-1 specific T cells [27].